Latest technologies from Mount Sinai School of Medicinehttp://msip.technologypublisher.comBe the first to know about the latest inventions and technologies available from Icahn School of Medicine at Mount Sinaien-USSun, 16 Dec 2018 12:11:38 GMTFri, 14 Dec 2018 10:25:26 GMThttp://blogs.law.harvard.edu/tech/rsstechnology@mssm.eduCopyright 2018, Mount Sinai School of MedicineMRI Compatible Foot Stressor Devicehttp://msip.technologypublisher.com/technology/30343Fri, 14 Dec 2018 10:25:26 GMTtechnology@mssm.eduhttp://msip.technologypublisher.com/technology/30343Topoisomerase 1 (Top1) inhibition as a novel treatment strategy for sepsis and cytokine release syndromehttp://msip.technologypublisher.com/technology/30342Fri, 14 Dec 2018 10:22:47 GMTtechnology@mssm.eduhttp://msip.technologypublisher.com/technology/30342Antibody against Follicle Stimulating Hormone to Reduce Metabolic-Related Disordershttp://msip.technologypublisher.com/technology/30341Fri, 14 Dec 2018 09:45:26 GMTtechnology@mssm.eduhttp://msip.technologypublisher.com/technology/30341Genipin-Crosslinked Fibrin Hydrogels for Intervertebral Disc Repairhttp://msip.technologypublisher.com/technology/30340Fri, 14 Dec 2018 09:43:03 GMTtechnology@mssm.eduhttp://msip.technologypublisher.com/technology/30340Method for Multiple Enzymatic Labelling of Formalin-Fixed Paraffin-Embedded Tissue on a Single Slidehttp://msip.technologypublisher.com/technology/30339Fri, 14 Dec 2018 09:38:20 GMTtechnology@mssm.eduhttp://msip.technologypublisher.com/technology/30339Cepharanthine as a repurposing opportunity in autoimmune thyroiditishttp://msip.technologypublisher.com/technology/30327Wed, 12 Dec 2018 14:17:19 GMTtechnology@mssm.eduhttp://msip.technologypublisher.com/technology/30327Method to determine causal relationships in complex networkshttp://msip.technologypublisher.com/technology/30326Wed, 12 Dec 2018 14:12:10 GMTtechnology@mssm.eduhttp://msip.technologypublisher.com/technology/303263D-Printed Droplet Interface Bilayer Scaffolds for Ensemble and Single Channel Biophysicshttp://msip.technologypublisher.com/technology/30325Wed, 12 Dec 2018 14:09:31 GMTtechnology@mssm.eduhttp://msip.technologypublisher.com/technology/30325Automated Facial Grading System for Evaluation and Treatment of Facial Paralysishttp://msip.technologypublisher.com/technology/30324Wed, 12 Dec 2018 14:07:35 GMTtechnology@mssm.eduhttp://msip.technologypublisher.com/technology/30324A System to Control Protein Degradation in Mammalian Cells Using Plant Hormoneshttp://msip.technologypublisher.com/technology/30323Wed, 12 Dec 2018 14:02:35 GMTtechnology@mssm.eduhttp://msip.technologypublisher.com/technology/30323Use of REDD1 Inhibitors to Dissociate Therapeutic and Adverse Atrophogenic Effects of Glucocorticoid Receptor Agonistshttp://msip.technologypublisher.com/technology/30286SummaryInhibitors of the REDD1 transcription factor that dissociate the therapeutic and pathological effects of GR agonistsUnmet needThe glucocorticoid receptor (GR) is a ligand specific transcription factor that mediates the biological effect of glucocorticoids. GR agonists are used for their anti-inflammatory and anti-proliferative effects which are mediated via inhibition of endogenous GR function thus reducing the expression of many genes activated by glucocorticoid binding. However, many metabolic negative side-effects can result from GR agonists including glucocorticoid-induced skin atro...Fri, 07 Dec 2018 12:21:44 GMTtechnology@mssm.eduhttp://msip.technologypublisher.com/technology/30286Antibodies Enhanced For Protection Against Influenza (GG3 Antibody)http://msip.technologypublisher.com/technology/30285SummaryMonoclonal antibodies that can detect and neutralize a broad range of influenza A strains that are infectious to humans.Unmet needInfluenza A and B viruses are major human pathogens, causing a respiratory disease that ranges in severity from sub-clinical infection to primary viral pneumonia which can result in death. The cumulative morbidity and mortality caused by seasonal influenza is substantial due to the relatively high rate of infection. In a normal season, influenza can cause between 3-5 million cases of severe illness and is associated with 200,000 to 500,000 deaths worldwide.An...Fri, 07 Dec 2018 12:19:05 GMTtechnology@mssm.eduhttp://msip.technologypublisher.com/technology/30285Use of Shroom3 in Chronic Kidney Disease and Chronic Allograft Nephropathyhttp://msip.technologypublisher.com/technology/30284SummaryA method for identifying a kidney transplant recipient at an increased risk of developing interstitial fibrosis or tubular atrophy, two conditions that can lead to rejection of the transplanted organ.Unmet needChronic kidney disease CKD affects 10% of US adults and the incidence and prevalence continues to rise globally. CKD can progress to End-stage renal disease (ESRD) whih requires renal replacement therapy (RRT) and currently affects over 500,000 US adults. Tubulo-interstitial fibrosis (TIF) is a final common pathogenic process of CKD that can lead to the development of ESRD. Furthe...Fri, 07 Dec 2018 12:17:06 GMTtechnology@mssm.eduhttp://msip.technologypublisher.com/technology/30284Predicting Risk of Exposure to Interstitial Fibrosis and Tubular Atrophy using Clusterinhttp://msip.technologypublisher.com/technology/30283SummaryA method for identifying a kidney transplant recipient at an increased risk of developing interstitial fibrosis or tubular atrophy, two conditions that can lead to rejection of the transplanted organ.Unmet needChronic kidney disease CKD affects 10% of US adults and the incidence and prevalence continues to rise globally. CKD can progress to End-stage renal disease (ESRD) which requires renal replacement therapy (RRT) and currently affects over 500,000 US adults. Tubulo-interstitial fibrosis (TIF) is a final common pathogenic process of CKD that can lead to the development of ESRD. Furth...Fri, 07 Dec 2018 12:14:20 GMTtechnology@mssm.eduhttp://msip.technologypublisher.com/technology/30283Targeting AML through novel irreversible FLT3 inhibitorhttp://msip.technologypublisher.com/technology/30282SummaryGain of function duplication mutations of FLT3 contribute to the 60% relapse rate that occurs in elderly Acute Myeloid Leukemia (AML) patients following treatment. MS150030 is an orally bio-available small molecule that irreversibly binds to and inhibits the active form of FLT3 negating the increased FLT3 activity produced via the duplication mutation and thus has the potential to reduce relapse, increasing survival rates following treatment for AML. Unmet needAML is caused due to rapid proliferation of myeloid progenitor cells in bone marrow. Elderly patients are particularly at risk w...Fri, 07 Dec 2018 12:11:57 GMTtechnology@mssm.eduhttp://msip.technologypublisher.com/technology/30282Small Molecule Transcription Modulators of Bromodomains for the Treatment of Cancer and Inflammatory Diseasehttp://msip.technologypublisher.com/technology/30033SummaryThis technology relates to selective small molecule modulators of individual bromodomains for treating cancer and neuro-inflammatory disease.Unmet needThe bromodomain (BrD) is a conserved protein modular domain found in many chromatin- and transcription-associated proteins that can recognize acetylated lysine residues. This activity allows bromodomains to play a vital role in many acetylation-mediated protein-protein interactions in the cell, ranging from substrate recruitment for histone acetyltransferases (HATs) to aiding in multiple-protein complex assembly for gene transcriptional a...Tue, 04 Dec 2018 12:57:09 GMTtechnology@mssm.eduhttp://msip.technologypublisher.com/technology/30033 Autism Mental Status Examinationhttp://msip.technologypublisher.com/technology/30032Tue, 04 Dec 2018 12:54:26 GMTtechnology@mssm.eduhttp://msip.technologypublisher.com/technology/30032Follicle Stimulating Hormone Receptor Predicts Responsiveness to Kinase Inhibitor Treatment in Cancerhttp://msip.technologypublisher.com/technology/30031Tue, 04 Dec 2018 12:51:58 GMTtechnology@mssm.eduhttp://msip.technologypublisher.com/technology/30031Wide Spectrum Antiviral Compoundshttp://msip.technologypublisher.com/technology/30030Tue, 04 Dec 2018 12:48:49 GMTtechnology@mssm.eduhttp://msip.technologypublisher.com/technology/30030Compositions and Methods for Inhibiting Human Host Factors Required for Influenza Virus Replicationhttp://msip.technologypublisher.com/technology/30029Tue, 04 Dec 2018 12:30:20 GMTtechnology@mssm.eduhttp://msip.technologypublisher.com/technology/30029Insulin-like Growth Factor-1 (IGF-1) Treatment for Phelin-McDermid Syndroms (PMS)http://msip.technologypublisher.com/technology/29949Mon, 03 Dec 2018 13:20:00 GMTtechnology@mssm.eduhttp://msip.technologypublisher.com/technology/29949A Treatment for Inflammation Utilizing Pentosan Polysulfate (PPS)http://msip.technologypublisher.com/technology/29943Mon, 03 Dec 2018 13:16:34 GMTtechnology@mssm.eduhttp://msip.technologypublisher.com/technology/29943Influenza Viruses and uses thereofhttp://msip.technologypublisher.com/technology/29942Mon, 03 Dec 2018 13:13:24 GMTtechnology@mssm.eduhttp://msip.technologypublisher.com/technology/29942Antibodies Targeting CB1/AT1R or CB1/A2aR Heteromers to Treat Liver Fibrosishttp://msip.technologypublisher.com/technology/29941Mon, 03 Dec 2018 13:12:06 GMTtechnology@mssm.eduhttp://msip.technologypublisher.com/technology/29941Monoclonal Antibodies Against Influenza Virus Generated By Cyclical Administrationhttp://msip.technologypublisher.com/technology/29924Mon, 03 Dec 2018 13:08:58 GMTtechnology@mssm.eduhttp://msip.technologypublisher.com/technology/29924Novel Therapy for Treatment of Hemoglobinopathies (Beta-Thalassemia and Sickle Cell Disease)http://msip.technologypublisher.com/technology/29892Fri, 30 Nov 2018 14:46:19 GMTtechnology@mssm.eduhttp://msip.technologypublisher.com/technology/29892Myeloid- derived suppressor cells (MDSCs) Mediated Tumor Targetinghttp://msip.technologypublisher.com/technology/29891Fri, 30 Nov 2018 14:44:12 GMTtechnology@mssm.eduhttp://msip.technologypublisher.com/technology/29891Soft Tissue Sampling Toolhttp://msip.technologypublisher.com/technology/29890Fri, 30 Nov 2018 14:41:39 GMTtechnology@mssm.eduhttp://msip.technologypublisher.com/technology/29890Small Molecular Weight Compounds to Inhibit or Enhance Influenza A Replicationhttp://msip.technologypublisher.com/technology/29889Fri, 30 Nov 2018 14:37:41 GMTtechnology@mssm.eduhttp://msip.technologypublisher.com/technology/29889Novel high throughput screen to identify regulators of ubiquitin ligase activityhttp://msip.technologypublisher.com/technology/29888Fri, 30 Nov 2018 14:29:52 GMTtechnology@mssm.eduhttp://msip.technologypublisher.com/technology/29888